Gly-His-Lys (GHK) peptide corrects immuno-metabolic disorders and boosts hepatocyte mitosis in CCl4-induced liver damage.
Background
Acute toxic liver damage, often induced by agents like tetrachloromethane (CCl4), leads to severe hepatocyte necrosis, inflammation, and impaired liver function. Current treatments primarily focus on supportive care, but there's a significant need for agents that can actively promote liver regeneration and modulate the accompanying immune dysregulation. The tripeptide Gly-His-Lys (GHK) is a naturally occurring human peptide known for its roles in wound healing, tissue regeneration, and anti-inflammatory processes, making it a compelling candidate for addressing the complex immuno-metabolic disturbances seen in liver injury.
Study Design
Researchers investigated the effects of Gly-His-Lys peptide on acute toxic liver damage induced by CCl4 in mice and rats. Animals received intraperitoneal injections of Gly-His-Lys daily for 10 days at three different doses: 1.5 µg/kg, 2.5 µg/kg, and 150 µg/kg. The study assessed several key parameters, including the mitotic index of hepatocytes, functional activity of hepatocytes, immunological responsiveness, biochemical indices of blood serum (e.g., liver enzymes), and histopathological dystrophic changes in liver tissue to evaluate the peptide's therapeutic potential.
Results
The study revealed a dose-dependent effect of Gly-His-Lys on liver regeneration and immune modulation. Both the 2.5 µg/kg and 150 µg/kg doses of Gly-His-Lys significantly raised the mitotic index of hepatocytes, indicating enhanced cellular proliferation and regenerative capacity in the acutely damaged liver. Crucially, the 1.5 µg/kg dose of Gly-His-Lys demonstrated a balanced corrective action, improving both the functional activity of hepatocytes and immunological responsiveness. This suggests an optimal therapeutic window for immune-metabolic correction. However, the highest dose, 150 µg/kg, while still promoting hepatocyte mitosis, exhibited a more potent immunosuppressive action.
Key Findings
- Gly-His-Lys at 2.5 µg/kg and 150 µg/kg increased hepatocyte
mitotic indexin CCl4-damaged liver. - A 1.5 µg/kg dose of Gly-His-Lys corrected hepatocyte
functional activityandimmunological responsiveness. - The 150 µg/kg dose of Gly-His-Lys showed potent
immunosuppressionbut worsenedbiochemical indicesand liverdystrophy.
Why It Matters
This research highlights the significant potential of Gly-His-Lys (GHK) as a therapeutic agent for acute liver damage, particularly in its ability to promote regeneration and modulate immune responses. The findings underscore the critical importance of dose optimization for GHK, as a lower dose (1.5 µg/kg) achieved a balanced correction of liver function and immunity, while a much higher dose (150 µg/kg) led to undesirable immunosuppression and worsened biochemical and histological markers. For peptide users and biohackers, this implies that GHK's benefits are highly dose-dependent, and higher doses are not necessarily better, potentially leading to adverse effects. Future clinical translation would require careful dose-finding studies to identify the optimal therapeutic window for human application, moving beyond the preclinical-animal model.
gly-his-lys
ghk
liver-damage
carbon-tetrachloride
hepatoprotection
immunosuppression